March 2, 2020 / 2:43 PM / a month ago

BRIEF-Rhythm Pharmaceuticals Reports Q4 Net Loss Per Common Share $0.78

March 2 (Reuters) - Rhythm Pharmaceuticals Inc:

* RHYTHM PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

* QTRLY NET LOSS PER COMMON SHARE $0.78

* RHYTHM PHARMACEUTICALS - EXPECTS EXISTING CASH, EQUIVALENTS & SHORT-TERM INVESTMENTS WILL ENABLE CO TO FUND OPERATIONS THROUGH AT LEAST END OF 2021

* ON TRACK TO COMPLETE ROLLING NDA SUBMISSION TO FDA FOR SETMELANOTIDE IN POMC AND LEPR DEFICIENCY OBESITIES IN Q1 OF 2020

* GRANTED ORPHAN DRUG DESIGNATION BY EUROPEAN MEDICINES AGENCY FOR SETMELANOTIDE IN ALSTRÖM SYNDROME

* RHYTHM PHARMACEUTICALS - EXPECTS TO REPORT TOPLINE DATA FROM PHASE 3 TRIAL OF SETMELANOTIDE IN BBS & ALSTRÖM SYNDROME IN Q4 2020 OR EARLY Q1 2021

* Q4 EARNINGS PER SHARE VIEW $-0.89 — REFINITIV IBES DATA

* RHYTHM PHARMACEUTICALS - EXPECTS TO SUBMIT IND APPLICATION FOR RM-853 FOR TREATMENT OF PRADER-WILLI SYNDROME TO FDA IN 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below